--- title: How has the global burden of PMS and uterine fibroids changed since 1990, and where is it heading by 2050? description: Worldwide, an estimated 233 million women had PMS in 2023, and both PMS and uterine fibroids have become slightly more common since 1990, with uterine fibroid url: https://niyora.com/research/papers/global-burden-of-premenstrual-syndrome-and-uterine-fibroids-in-women-of-2026/ --- - [Niyora](https://niyora.com/) - [Research](https://niyora.com/research/) - [Library](https://niyora.com/research/library/) - How has the global burden of PMS and uterine fibroids changed since 1990, and where is it heading by 2050? Survey study, 2026 # How has the global burden of PMS and uterine fibroids changed since 1990, and where is it heading by 2050? Worldwide, an estimated 233 million women had PMS in 2023, and both PMS and uterine fibroids have become slightly more common since 1990, with uterine fibroids rising faster and expected to keep rising sharply through 2050. Moderate study design Women aged 15-49 worldwide, using global data from 1990 to 2023 ## What they did Researchers used the Global Burden of Disease 2023 database to track how common PMS and uterine fibroids were in women aged 15 to 49 worldwide from 1990 to 2023, and used statistical models to project trends forward to 2050. ## What they found In 2023 there were about 233,405,777 cases of PMS and 10,017,494 cases of uterine fibroids globally. From 1990 to 2023, PMS prevalence rose slightly (EAPC 0.06%, 95% CI 0.04 to 0.07) while uterine fibroid prevalence rose more (EAPC 0.58%, 95% CI 0.53 to 0.62). Projections to 2050 suggest PMS prevalence may dip slightly while related disability rises a little, whereas uterine fibroids are expected to keep rising substantially. More developed countries had higher rates of both (PMS r=0.351, UF r=0.381, p<0.0001). PMS burden was highest in women aged 15-30, while uterine fibroid burden was highest in women aged 35-49. ## What it means for you This shows PMS remains a very widespread issue worldwide, especially in younger women, while uterine fibroids are a growing concern, especially with age. It is a descriptive analysis of modelled global data, not a study of treatments, so it cannot explain why rates are changing. 233,405,777 PMS cases worldwide in 2023 10,017,494 Uterine fibroid cases worldwide in 2023 0.06% Yearly change in PMS prevalence (EAPC) ## About the study Original title Global Burden of Premenstrual Syndrome and Uterine Fibroids in Women of Reproductive Age (1990-2023) and Projections to 2050: An Analysis of the Global Burden of Disease Study 2023 Authors Xiaoli D, Qiang Y, Jun W et al. Journal Health science reports Year 2026 Study design Survey study What was tested None, this was an analysis of global disease burden data, not a treatment study Open access Yes Read the paper [doi.org/10.1002/hsr2.72602](https://doi.org/10.1002/hsr2.72602) Original abstract Background: Premenstrual syndrome (PMS) and uterine fibroids (UF) are major gynecological diseases that markedly affect the reproductive health of women of reproductive age (WRA). This study aimed to provide updated global estimates of these disorders among WRA (15-49 years) between 1990 and 2023 and to forecast future trends. Methods: Data from the GBD 2023 were used to assess the temporal trend and future projections of PMS and UF among WRA. Estimated annual percent change (EAPC), ARIMA model, and Pearson correlation analysis were used to assess temporal trends (1990-2023), forecast projections (2024-2050), and examine the association of socio-demographic index (SDI) with major gynecological disorders, respectively. Results: In 2023, the global incidence was approximately 233,405,777 cases of PMS and 10,017,494 cases of UF. Between 1990 and 2023, the age-standardized prevalence rates of PMS and UF among WRA increased, with EAPC of 0.06% (95% CI: 0.04, 0.07) and 0.58% (95% CI: 0.53, 0.62), and the corresponding age-standardized disability-adjusted life years (DALYs) rates also increased, with EAPC of 0.05% (95% CI: 0.03, 0.07) and 1.21% (95% CI: 1.01, 1.42), respectively. Projections to 2050 indicate a slight decline in PMS prevalence rates but a mild increase in DALY rates, whereas both the prevalence and DALY rates of UF are expected to rise substantially. The burden and temporal patterns of PMS and UF varied markedly across countries, regions, and SDI levels. The prevalence rates of PMS (r = 0.351) and UF (r = 0.381) showed significant positive correlations with SDI ( p < 0.0001). The PMS burden was highest among women aged 15-30 years, while women aged 35-49 years showed a greater burden of UF. Conclusion: The global burden of PMS and UF has increased over the last 34 years, underscoring the need for targeted public health strategies to improve reproductive health in women. Reproduced under CC-BY. ## Topics [Premenstrual syndrome (PMS)](https://niyora.com/research/topics/condition-pms/)[Work and productivity](https://niyora.com/research/topics/life-area-work/)[Quality of life and daily functioning](https://niyora.com/research/topics/life-area-quality-of-life/) Research tells you what helps on average. Niyora helps on the day it hits. Calm down, see it another way, and decide what to say, with a PMS and PMDD app built by a doctor. ## Related studies Cohort study, 2026 Is PMS becoming more common and more disabling worldwide? Systematic review, 2026 Do mindfulness and relaxation techniques help with PMS symptoms? Systematic review, 2025 Do nutritional interventions help with emotional symptoms of PMS? Systematic review, 2025 Does digital healthcare help manage period pain and PMS? Cohort study, 2025 Do women with premenstrual disorders take more sick leave and have higher unemployment? Systematic review, 2025 How common are PMS, PMDD, and painful periods in nursing students, and do they affect their schooling? Ask AI about this page Copy prompt ChatGPT ↗ Claude ↗ Perplexity ↗ Google AI Mode ↗ Grok ↗